Pulmonary arterial hypertension presents severe hemodynamic challenges characterized by progressive vascular remodeling and elevated pulmonary arterial pressure. Recent cardiovascular investigations have highlighted how gonadal steroid metabolites influence vascular tone through pathways distinct from classical nuclear receptors. A groundbreaking laboratory investigation evaluated isolated vascular tissue to clarify how androgens affect vascular beds. Specifically, the study revealed that nongenomic pulmonary artery vasodilation occurs rapidly following exposure to 5β-dihydrotestosterone, demonstrating notable vascular responsiveness without triggering classical androgenic receptor activation.

Vascular Tone and the Influence of Androgen Metabolites

For decades, cardiovascular medicine viewed androgens primarily through the lens of classical reproductive biology. Consequently, many clinicians assumed male sex hormones solely exerted deleterious effects on systemic vascular resistance. However, expanding pharmacological evidence indicates that testosterone and its downstream enzymatic metabolites actively regulate acute smooth muscle tension. In peripheral circulation, testosterone undergoes enzymatic reduction via 5α-reductase or 5β-reductase pathways. The resulting metabolite, 5β-dihydrotestosterone, exhibits distinct stereochemical properties that prevent classical genomic transcription. Therefore, this reduced androgen cannot stimulate typical androgen-dependent tissue growth or secondary sexual characteristics.

Instead, the compound directly interacts with vascular smooth muscle membranes to modify arterial diameter. Furthermore, experimental evaluations across multiple mammalian systemic vascular beds show marked vasorelaxation after administration of this molecule. Because pulmonary vasculature possesses unique electrophysiological properties compared to systemic arteries, exploring local pulmonary reactivity became critical. Accordingly, researchers designed isometric tension experiments using pre-constricted rat pulmonary vessels. These initial findings established that 5β-dihydrotestosterone induces immediate relaxation in pulmonary arterial rings, challenging older paradigms regarding androgenic influences on pulmonary vascular hemodynamics.

Differential Vasodilating Potency in Male and Female Vasculature

To evaluate sexual dimorphism, investigators compared responses between female and male pulmonary arterial segments. Notably, pre-constriction with potassium chloride permitted accurate assessment of cumulative concentration-response curves. The precursor molecule, testosterone, elicited similar vasodilatory potency in both sexes without significant divergence. In contrast, 5β-dihydrotestosterone exhibited dramatically enhanced potency compared to its parent androgen. Specifically, the metabolite was 2.2 times more potent than testosterone in female pulmonary arteries. Even more remarkably, 5β-dihydrotestosterone demonstrated 6.6 times greater potency than testosterone in male pulmonary vessels.

Additionally, the metabolite achieved superior overall efficacy in relaxing male pulmonary tissue compared to testosterone. Thus, the rank order of vasodilating potency demonstrated a clear hierarchy favoring 5β-dihydrotestosterone over testosterone across both sexes. Furthermore, the magnitude of this shift underscores important sex-dependent sensitivity within pulmonary vascular smooth muscle. Although both sexes responded robustly, male arteries exhibited a more pronounced shift in pharmacological sensitivity. Consequently, these outcomes suggest that local enzymatic metabolism of androgens might modulate baseline pulmonary vascular tone differently between males and females.

Mechanisms Underlying Pulmonary Artery Vasodilation

Understanding the intracellular cascade is essential for defining the clinical utility of any vasodilator. In these pulmonary experiments, 5β-dihydrotestosterone produced immediate vasorelaxation with a rapid onset. Moreover, the vasodilatory action reversed completely following standard washout procedures. Such rapid kinetics strongly argue against classic genomic steroid pathways that require nuclear translocation and protein synthesis. To rigorously verify this hypothesis, researchers pretreated pulmonary arterial preparations with transcription and protein synthesis inhibitors.

Crucially, neither transcriptional blockade nor protein synthesis inhibition altered the vasodilating action of 5β-dihydrotestosterone. Therefore, the metabolite operates entirely via nongenomic signaling cascades within vascular smooth muscle cells. Structural conformation appears to explain this unique pharmacological profile. The 5β-reduction introduces a severe bend in the steroid ring structure, eliminating affinity for classic nuclear androgen receptors. Consequently, the molecule avoids gene transcription while effectively interacting with plasma membrane channels. Previous systemic studies indicate that this configuration modulates calcium entry through L-type voltage-dependent channels and enhances potassium conductance. Ultimately, these membrane-bound actions trigger rapid smooth muscle hyperpolarization and sustained vasorelaxation.

Therapeutic Implications for Pulmonary Hypertension

Pulmonary arterial hypertension remains an incurable condition characterized by elevated pulmonary vascular resistance, right ventricular hypertrophy, and eventual right heart failure. Although modern therapeutic regimens utilize prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase inhibitors, mortality remains unacceptably high. Therefore, identifying novel molecular pathways capable of selective pulmonary relaxation represents an urgent priority. The discovery that 5β-dihydrotestosterone acts as a potent pulmonary vasodilator provides compelling avenues for drug development.

Because 5β-dihydrotestosterone lacks classic androgenic or estrogenic properties, it avoids undesirable endocrine side effects. For instance, classical testosterone therapy carries risks of prostatic hypertrophy, polycythemia, and virilization in females. Conversely, a 5β-reduced steroid analog provides vascular benefit without stimulating hormone-sensitive reproductive tissues. Furthermore, the rapid and reversible nature of this vasodilation offers excellent pharmacodynamic control for acute hemodynamic interventions. In addition, the notable efficacy observed in male arteries could help address sex-specific differences in pulmonary hypertension prognosis. Thus, synthetic molecules mimicking the 5β-androgen structure could potentially serve as targeted pulmonary vasodilators.

Translational Potential and Preclinical Research Directions

Translating these preclinical findings into human clinical trials requires systematic validation across diseased vascular models. Currently, the experimental data derive from healthy rat pulmonary rings pre-constricted with potassium chloride. However, pulmonary hypertension involves severe endothelial dysfunction, medial hypertrophy, and plexiform lesions. Therefore, future studies must evaluate 5β-dihydrotestosterone in chronic hypoxia and monocrotaline-induced pulmonary hypertension models. Such animal models will demonstrate whether diseased, remodeled vessels retain sensitivity to 5β-reduced metabolites.

Furthermore, researchers must delineate whether the vasorelaxation relies partially on endothelial nitric oxide synthase or acts strictly upon vascular smooth muscle. In addition, pharmacokinetic studies are necessary to evaluate bioavailability, clearance, and metabolic stability in vivo. Because intravenous administration could potentially cause systemic hypotension, developing inhaled aerosolized formulations represents an attractive delivery strategy. Inhaled administration would deliver the active metabolite directly to pulmonary alveolar capillaries, maximizing pulmonary selectivity while minimizing systemic arterial hypotension. Ultimately, these ongoing preclinical investigations provide a solid foundation for novel therapeutic strategies targeting severe cardiopulmonary disorders.

How does 5β-dihydrotestosterone differ from classical testosterone in vascular tissue?

Unlike testosterone, 5β-dihydrotestosterone possesses a distinct three-dimensional conformation resulting from 5β-reduction. Consequently, this metabolite lacks affinity for classic nuclear androgen receptors and cannot stimulate genomic transcription. Instead, it triggers rapid nongenomic vasorelaxation by acting directly on smooth muscle plasma membranes. Furthermore, it demonstrates significantly higher vasodilating potency and efficacy in pulmonary arterial tissue than testosterone, without inducing undesirable hormonal or proliferative side effects in reproductive organs.

Why is the nongenomic mechanism critical for treating pulmonary arterial hypertension?

Classical genomic pathways require nuclear receptor binding, gene transcription, and protein synthesis, taking hours to produce biological effects. In contrast, nongenomic signaling operates within seconds to minutes, providing immediate vascular relief. Moreover, because this mechanism bypasses gene activation entirely, experimental protein synthesis inhibitors do not diminish its vasodilating potency. Therefore, acute nongenomic pulmonary relaxation offers rapid hemodynamic control while avoiding long-term endocrine changes or nuclear transcription in vulnerable vascular tissue.

What sex-related differences were observed in pulmonary arterial responses?

Although testosterone displayed identical vasodilatory potency across both sexes, 5β-dihydrotestosterone demonstrated pronounced sexual dimorphism. In female pulmonary arteries, the metabolite was 2.2 times more potent than testosterone. Remarkably, in male pulmonary arteries, 5β-dihydrotestosterone was 6.6 times more potent than testosterone and achieved significantly greater efficacy. Consequently, these findings indicate that male pulmonary vessels possess heightened pharmacodynamic sensitivity to 5β-reduced metabolites, suggesting potential therapeutic advantages tailored to sex-specific vascular physiology.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Herrera N et al. Study of the rapid vasodilating effect induced by 5β-dihydrotestosterone in the isolated pulmonary arteries of female and male rats. Endocr Res. 2026 Oct 14. doi: 10.1080/07435800.2026.2748590. PMID: 42875376.
2. Sánchez-Fernández D, Eguibar A, López C, Cuesta ÁM, Albiñana V, Rogers-Ezewuike S, et al. Effect of 5β-dihydrotestosterone on vasodilator function and on cell proliferation. PLoS One. 2024;19(10):e0312080. doi: 10.1371/journal.pone.0312080.
3. Perusquía M, Stallone JN. Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol Heart Circ Physiol. 2010;298(5):H1301-H1307. doi: 10.1152/ajpheart.00753.2009.
4. Jones RD, English KM, Jones TH, Channer KS. Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag. 2008;4(4):861-869. doi: 10.2147/vhrm.s3311.